Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2020-11-11 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Appendix 2A 15 pages 218.2KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities to be quoted, and references to previous announcements such as Appendix 3B. The document is a regulatory form used to notify the exchange about new securities being listed or quoted. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement but a formal regulatory filing required by the exchange. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-11-11 English
Appendix 2A 15 pages 218.2KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, and the nature of the issue (e.g., options exercised or convertible securities converted). This type of document is a regulatory announcement related to capital markets activity, specifically the quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document fits the category of Capital/Financing Update (CAP) because it updates the market on the issuance and quotation of new securities, which affects the company's capital structure.
2020-11-05 English
Disclosure Document 38 pages 403.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Prospectus' and details a Placement Offer for shares in Neurotech International Limited. It includes information about the offer price, number of shares, use of funds, risk factors, and legal disclaimers. The document is a formal offer to investors to purchase shares and raise capital, which aligns with a capital raising or financing activity. It is not an annual report, earnings release, or any other type of report. The key indicators are the terms 'Prospectus', 'Placement Offer', 'offer price', 'shares to be issued', and 'use of funds'. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is the actual offer document, not just an announcement of a report, so it is not RPA or RNS.
2020-11-05 English
Quarterly Report and Appendix 4C 9 pages 287.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Report for the period ended 30 September 2020' and contains detailed operational highlights, research updates, commercial agreements, board changes, and a comprehensive Appendix 4C cash flow report as required by ASX Listing Rule 4.7B. The presence of substantive financial data such as cash flows from operating, investing, and financing activities confirms this is a financial report for a period shorter than a full fiscal year. The detailed nature and inclusion of financial statements align with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the correct classification is IR with high confidence. Q1 2021
2020-11-01 English
Interim Results and Capital Raising 3 pages 101.7KB
Capital/Financing Update Classification · 95% confidence The document contains two main parts: first, preliminary scientific results from in vitro studies on proprietary cannabis strains, and second, an announcement of a $2.5 million share placement (capital raising) by Neurotech International Limited. The scientific results are preliminary and do not constitute a formal financial or management report. The share placement details include the number of shares, issue price, use of funds, and conditions such as shareholder approval. This is a clear update on the company's financing activities rather than a full financial report or earnings release. There is no indication of a full annual or interim report, earnings highlights, or management discussion of financial results. The document is primarily an announcement of capital raising and related financing terms. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7456 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2020-11-01 English
Proposed issue of Securities - NTI 5 pages 28.2KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a proposed issue of securities by Neurotech International Limited. It details the number of securities to be issued, the issue price, the proposed issue date, approvals required, fees to be paid to the lead manager, and the purpose of the funds raised. There are no financial statements or detailed financial performance data included. The document is focused on informing about a capital raising activity, specifically a placement of new shares. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length is over 5,000 characters and contains substantive details about the financing event, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is CAP with high confidence.
2020-11-01 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.